Tags

Type your tag names separated by a space and hit enter

Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias.
Am Heart J. 1987 Aug; 114(2):296-302.AH

Abstract

The efficacy and safety of intravenous tocainide were compared with intravenous lidocaine in patients with chronic ventricular arrhythmias in a double-blind, parallel study. Twenty-nine patients were randomized to a tocainide (n = 15) or lidocaine (n = 14) group. Antiarrhythmic efficacy was defined as a greater than or equal to 50% reduction in single ventricular premature complex (VPC) frequency, greater than or equal to 90% reduction in paired VPC frequency, and total abolition of ventricular tachycardia. Efficacy was observed in 40% (6 of 15) of patients in the tocainide group and in 36% (5 of 14) patients in the lidocaine group. A 75% or greater reduction in total VPCs occurred in 40% (6 of 15) of patients in the tocainide group and in 57% (8 of 14) of patients in the lidocaine group. Greater than 90% suppression of paired VPCs occurred in 9 of 13 (69%) patients taking tocainide and in 6 of 11 (54%) patients taking lidocaine. Total abolition of ventricular tachycardia was documented in 5 of 11 (45%) patients given tocainide and in two of six (33%) patients given lidocaine. A total of 17 adverse reactions affecting 86% (12 of 14) of patients taking lidocaine and 11 adverse reactions affecting 53% (8 of 15) of patients taking tocainide occurred. Four patients in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous tocainide are similar to that of intravenous lidocaine in patients with chronic ventricular arrhythmias.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

3111238

Citation

Mohiuddin, S M., et al. "Double-blind Randomized Comparison of Intravenous Tocainide Versus Lidocaine in the Treatment of Chronic Ventricular Arrhythmias." American Heart Journal, vol. 114, no. 2, 1987, pp. 296-302.
Mohiuddin SM, Hilleman DE, Mooss AN, et al. Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias. Am Heart J. 1987;114(2):296-302.
Mohiuddin, S. M., Hilleman, D. E., Mooss, A. N., Esterbrooks, D., Sketch, M. H., Stengel, L. A., & Butler, M. L. (1987). Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias. American Heart Journal, 114(2), 296-302.
Mohiuddin SM, et al. Double-blind Randomized Comparison of Intravenous Tocainide Versus Lidocaine in the Treatment of Chronic Ventricular Arrhythmias. Am Heart J. 1987;114(2):296-302. PubMed PMID: 3111238.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias. AU - Mohiuddin,S M, AU - Hilleman,D E, AU - Mooss,A N, AU - Esterbrooks,D, AU - Sketch,M H, AU - Stengel,L A, AU - Butler,M L, PY - 1987/8/1/pubmed PY - 1987/8/1/medline PY - 1987/8/1/entrez SP - 296 EP - 302 JF - American heart journal JO - Am Heart J VL - 114 IS - 2 N2 - The efficacy and safety of intravenous tocainide were compared with intravenous lidocaine in patients with chronic ventricular arrhythmias in a double-blind, parallel study. Twenty-nine patients were randomized to a tocainide (n = 15) or lidocaine (n = 14) group. Antiarrhythmic efficacy was defined as a greater than or equal to 50% reduction in single ventricular premature complex (VPC) frequency, greater than or equal to 90% reduction in paired VPC frequency, and total abolition of ventricular tachycardia. Efficacy was observed in 40% (6 of 15) of patients in the tocainide group and in 36% (5 of 14) patients in the lidocaine group. A 75% or greater reduction in total VPCs occurred in 40% (6 of 15) of patients in the tocainide group and in 57% (8 of 14) of patients in the lidocaine group. Greater than 90% suppression of paired VPCs occurred in 9 of 13 (69%) patients taking tocainide and in 6 of 11 (54%) patients taking lidocaine. Total abolition of ventricular tachycardia was documented in 5 of 11 (45%) patients given tocainide and in two of six (33%) patients given lidocaine. A total of 17 adverse reactions affecting 86% (12 of 14) of patients taking lidocaine and 11 adverse reactions affecting 53% (8 of 15) of patients taking tocainide occurred. Four patients in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous tocainide are similar to that of intravenous lidocaine in patients with chronic ventricular arrhythmias. SN - 0002-8703 UR - https://www.unboundmedicine.com/medline/citation/3111238/Double_blind_randomized_comparison_of_intravenous_tocainide_versus_lidocaine_in_the_treatment_of_chronic_ventricular_arrhythmias_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0002-8703(87)90494-7 DB - PRIME DP - Unbound Medicine ER -